Navigation Links
Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
Date:1/24/2008

Conference Call and Webcast Scheduled for Tuesday, February 5

SAN DIEGO, Jan. 24 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2007 financial results after the Nasdaq market closes on Tuesday, February 5, 2008. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Tuesday afternoon, February 5, 2008 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Participants can access the live conference call by dialing 800-862-9098, (US) or 785-424-1051 (International) using the conference ID: 7NBIX2. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com

If you are unable to attend the Webcast and would like further information on this announcement please contact the Investor Relations Department at Neurocrine Biosciences at (858) 617-7600. A replay of the Conference Call will be available approximately one hour after the conclusion of the call by dialing 1-800-723-0520 (US) or 402-220-2653 (International) using the conference ID: 7NBIX2. The call will be archived for two weeks.

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. The product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, irritable bowel syndrome, endometriosis and CNS related disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
2. Neurocrine Announces Work Force Restructuring
3. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
4. Neurocrine Biosciences Announces Conference Call and Webcast to Provide Indiplon Update
5. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2007 Financial Results
7. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
8. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
9. Neurocrine Biosciences to Present at the Bear Stearns Healthcare Conference
10. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
11. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a company developing ... food supply through enhancement of the gut microbiota, today announced the closing of its ... , New York-based Sustainable Income Capital Management, LLC and a number of private investors. ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ -  GeneNews Limited ... BreastSentry™ , a new risk stratification test for breast ... lab, Innovative Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker ... and lifetime risk for developing breast cancer.   ... BreastSentry measures the ...
(Date:3/28/2017)... ... March 28, 2017 , ... NetDimensions announced today ... and enhance training plan management for consistent implementation of standards and regulatory requirements ... SHL Group to help improve and streamline their training and employee development programs, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Ecovia ... Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). Under the ... to develop a suite of BioGel™ biopolymer materials for hygiene applications, particularly for ...
Breaking Biology Technology:
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):